FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 526 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR More than 65,000 people are left waiting to find out if... May 8, 2022 Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not... December 9, 2021 Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... February 18, 2025 Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent... July 24, 2023 Load more HOT NEWS CAR22 Shows Durable Efficacy After a Single Infusion in Patients with... Could food improve cancer treatment? – That Cancer Conversation A cut above: Making drug discovery more efficient using CRISPR EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan
